Antibody-based diagnostics are tests that utilize antibodies to detect specific molecules that are indicative of a particular disease or condition. These diagnostic tools leverage the high specificity of antibodies, and the ability to produce large quantities of them. For example, monoclonal antibodies (mAbs) can be developed to recognize unique antigenic determinants on specific pathogens associated with a disease.1
Various antibody-based diagnostic tests are now in use, including the enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests, western blotting, and immunohistochemistry.
In addition to detecting disease-associated molecules, antibody-based diagnostics may also be used to determine if someone has been previously exposed to a pathogen. For instance, tests for HIV or COVID-19 antibodies can determine if an individual was previously infected, even if no symptoms are shown.2
Types of Antibody-Based Diagnostic Tests
A range of antibody-based diagnostic techniques is currently employed in clinical and research settings. Some of the most widely used include:
Enzyme-Linked Immunosorbent Assay (ELISA): A staple in diagnostics, ELISA employs antibodies to detect and quantify antigens, such as proteins or pathogens, in biological samples. ELISA is commonly used for diagnostic tests such as those for HIV, hepatitis, and pregnancy. The test is highly sensitive and can be performed relatively quickly.
Rapid Diagnostic Tests (RDTs): RDTs use antibodies embedded in test strips to provide quick and portable diagnostic results. These tests are especially useful in point-of-care settings, such as diagnosing malaria or COVID-19 in a clinical environment where fast results are needed.
Western Blotting: A more specialized technique used to detect specific proteins within a sample. After separating proteins by size through gel electrophoresis, antibodies are used to bind target proteins. This method is often used to confirm the presence of HIV after an initial positive result from an ELISA.
Immunohistochemistry (IHC): IHC is used in pathology to detect the presence of specific antigens in tissues. This technique combines antibodies with chemical labels to visualize the distribution and localization of proteins in a tissue section. IHC is crucial in cancer diagnostics, helping to identify tumor markers and guide treatment decisions.
Each of these tests leverages the unique properties of antibodies to detect target antigens with a high degree of accuracy and reliability, making them invaluable in the early detection and monitoring of diseases.
Related: Antibody Basics: Part 11 - Diagnostics - ELISA, Western blot, fluorescence
Detecting Disease and Immune Responses
One of the critical advantages of antibody-based diagnostics is their ability to detect both active infections and prior exposure to pathogens. This feature is especially useful in situations where patients may not display overt symptoms but have been exposed to a pathogen. For instance:
HIV Testing: Antibody-based tests can detect HIV infection by identifying antibodies that the immune system produces in response to the virus. Even though HIV may remain dormant for years without symptoms, antibody tests can provide an early diagnosis, which is crucial for starting treatment before the disease progresses.
COVID-19 Serology Testing: Similar to HIV tests, COVID-19 antibody tests detect the presence of antibodies to SARS-CoV-2, the virus responsible for COVID-19. This can be used to assess whether an individual has previously been infected, even if they were asymptomatic. Serology testing was particularly useful during the pandemic to track the spread of the virus and determine immunity levels in populations.
Influenza and Hepatitis Detection: Influenza and hepatitis viruses are additional examples of pathogens that can be monitored through antibody-based tests. For hepatitis B, detecting antibodies against specific viral proteins helps determine both current and past infections, guiding treatment protocols and prevention strategies.
In each case, antibody-based diagnostics provide crucial information about a patient’s exposure history, immune response, and potential for transmission, guiding effective medical intervention and public health strategies.
The Role of Antibodies in Emerging Diagnostics
As antibody engineering techniques advance, the next generation of diagnostics is becoming even more precise, efficient, and adaptable to various medical and research needs. For example, the use of recombinant antibodies—antibodies generated through genetic engineering—opens up new possibilities in diagnostic innovation. Recombinant antibodies can be produced more quickly and in larger quantities than traditional monoclonal antibodies, offering greater flexibility in their application.
Furthermore, the rise of multiplex assays, which allow for the simultaneous detection of multiple biomarkers in a single sample, is revolutionizing diagnostic testing. Multiplex assays can significantly improve the throughput of diagnostic laboratories by reducing the need for multiple tests and enhancing diagnostic precision, especially in complex diseases such as cancer, autoimmune disorders, and infectious diseases.
Diagnostic companies and biotech firms are increasingly focused on optimizing these tests to detect lower concentrations of biomarkers, thereby improving the early detection of diseases such as cancer or Alzheimer’s, where early intervention can dramatically improve patient outcomes.
Siddiqui, M. Z. (2010). Monoclonal Antibodies as Diagnostics; an Appraisal. Indian Journal of Pharmaceutical Sciences, 72(1), 12-17. https://www.ijpsonline.com/archive.html
Deeks, J. J., Dinnes, J., Takwoingi, Y., Davenport, C., Spijker, R., Taylor-Phillips, S., Adriano, A., Beese, S., Dretzke, J., Harris, I. M., Price, M. J., Dittrich, S., Emperador, D., Hooft, L., Leeflang, M. M., & Accuracy Group, D. T. (2020). Antibody tests for identification of current and past infection with SARS‐CoV‐2. The Cochrane Database of Systematic Reviews, 2020(6). https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013652/full
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
